Educational Objectives:

On completion of this activity, the participants should be better able to:

  • Explain data on the prevalence and consequences of HCC
  • Demonstrate strategies to incorporate classification, diagnostic and treatment updates into clinical practice to individualize treatment strategies
  • Analyze recently approved and emerging treatment options and understand how new agents are improving the standard of care for all HCC patients
  • Describe effective models of multi-disciplinary care for patients with HCC

Accreditation Statement and Credit Designation for Virtual Activity:

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the New Mexico Medical Society (NMMS) through the joint providership of Rehoboth McKinley Christian Health Care Services (RMCHCS) and the Chronic Liver Disease Foundation. RMCHCS is accredited by the NMMS to provide continuing medical education for physicians.

RMCHCS designates this enduring material for a maximum of 4.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This enduring material is accredited from April 30, 2021 - April 30, 2022.

This activity is supported by educational grants from Bristol-Myers Squibb and Exelixis, Inc.

Accredited by

Provided by

Did you miss the virtual conference? View the archived presentations now!

Featured faculty from the Ronald Reagan UCLA Medical Center

Myron Tong, MD, PhD (Course Director)

Vatche Agopian, MD

Jihane Benhammou, MD, PhD

Joseph DiNorcia III, MD, MS

Richard Finn, MD

David Lu, MD

Siddharth Padia, MD

Steven S. Raman, MD

Saeed Sadeghi, MD

PRESENTATION TOPICS

CLDF Welcome and Opening Remarks

Aijaz Ahmed, MD

Epidemiology and Surveillance of HCC

Myron Tong, MD, PhD

Imaging of HCC Surveillance, Diagnosis, and Prognosis

David Lu, MD

Thermal Ablation for HCC

Steven S. Raman, MD

Transarterial Therapies for HCC: TACE and Y90

Siddharth Padia, MD

Update on the Front-Line Management of Advanced HCC

Richard Finn, MD

Second Line Therapies in HCC

Saeed Sadeghi, MD

Current Surgical Resection for Primary Liver Malignancies

Vatche Agopian, MD

Liver Transplantation for Patients With HCC

Joseph DiNorcia III, MD, MS

HCC Research Update: From Bedside to Bench-side and Back to Bedside

Jihane Benhammou, MD, PhD

Closing Remarks

Myron Tong, MD, PhD